Company / Capital Returned to Shareholders
MoonLake Immunotherapeutics Capital Returned to Shareholders History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$50
FY2024
5-year range
$0 / $6.2K
FY2021-FY2024
Trend
-
vs FY2023
Sector context
#47 of 52
Health Care
What the data says
Among 52 Health Care companies, MoonLake Immunotherapeutics is in the bottom 10% for capital returned to shareholders. Improved from $0 to $50 over the past 2 years.
Based on SEC 10-K filings.
$50 in FY2024 with a 3-year CAGR of -79.9%.
Improved from $0 to $50 over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -79.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 52This company $50 Sector average $1.3B
▼
-100.0% below sector average
Key checks
Key Insights
- 3-year CAGR of -79.9%, indicating a declining trend.
- Ranks #47 out of 52 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $50 | - |
| FY2023 | $0 | - |
| FY2022 | $0 | -100.0% |
| FY2021 | $6.2K | - |
| FY2020 | - | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026